Insider buying last 90 days
No open-market insider purchases were filed for CYTK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CYTK insider filing, plotted on the chart in Gekko.Open CYTK in Gekko
NASDAQ: CYTK
Cytokinetics (CYTK) Stock Analysis & Forecast
Sep 28 close
$66.16+1.50 (+2.3%)
Gekko Brief
AI summaryCytokinetics stock rose 2.15% this week amid strong second-quarter revenue of $28.6 million, largely driven by Myqorzo sales reaching $25.3 million. Executives outlined commercial expansion plans and cardiovascular pipeline priorities at a Bernstein investor symposium, including a "Vision 2030" plan targeting two approved therapies across three indications, 10 new molecular entities, and a presence in over 15 countries. Analysts have set an average 12-month price target of $109.90, with 14 of 15 firms rating the stock buy and one hold.
Shares closed at $66.16, sitting between the 50-day average of $74.86 and the 200-day average of $70.07, with the stock down 15.1% over one month and 24.2% over three months, though up 38.3% over one year. The GekkoIndex reads 71.7, placing CYTK in the Buying zone. Price sits 25.2% below Gekko Fair Value of $88.50.
The next earnings report is scheduled for 4 November 2026, after the close, 36 days away and outside a typical 20-trading-day holding window. Over the last 90 days, Congress recorded 1 buy and 0 sells, and one trailblazer holder is noted. Seasonality from this point in the calendar has averaged a 3.9% gain over the next 20 trading days across 5 years, rising in 4 of them. Typical volatility over a similar window has run 7.7%.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Cytokinetics price vs fair value
Close $66.16200-day averageGekko Fair Value $88.50
Cytokinetics quick facts
- Market cap
- $8.23B
- P/E ratio
- —
- Forward P/E
- 117.7
- EPS, TTM
- −$7.22
- Revenue, TTM
- $67.67M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.36
- Volume
- 2.55M avg 1.97M
- 1-year return
- +38.3%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±7.7%
- 50-day average
- $74.86
- 200-day average
- $70.07
- Next earnings
- Nov 4 after close
- Shares outstanding
- 139.0M
Cytokinetics swing-trade checklist
Cytokinetics scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $66.16 sits between the 50-day ($74.86) and 200-day ($70.07) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
71.7, Buying
Reading 71.7 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
25.2% below
Price is 25.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.9% on average
From this point in the calendar, the next 20 trading days averaged +3.9% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Cytokinetics stock chart and price history
Cytokinetics closed at $66.16 on Sep 28, 2026, +38.3% over the past year, inside a 52-week range of $47.87 to $88.31.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −15.1%
- 3 months
- −24.2%
- 6 months
- +5.9%
- 1 year
- +38.3%
The full CYTK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CYTK in Gekko
Follow Cytokinetics through every session
Put CYTK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CYTK in GekkoFree for 7 days. No credit card required.
About Cytokinetics
Cytokinetics is a biopharmaceutical company centered on muscle activators and muscle inhibitors designed to treat serious, debilitating conditions in the United States. It has brought to market MYQORZO, an oral small molecule that inhibits cardiac myosin and is used for symptomatic oHCM, and this is the therapy for which the company is best recognized.
Beyond its marketed product, the company's pipeline includes Aficamten, another oral cardiac myosin inhibitor aimed at HCM, and omecamtiv mecarbil, which is being studied as a possible treatment spanning various stages of heart failure with severely reduced ejection fraction. It is also advancing Ulacamten, an oral cardiac myosin inhibitor intended to ease hypercontractility linked to heart failure with preserved ejection fraction, along with CK-089, a fast skeletal muscle troponin activator, with both of these in Phase 1 clinical trials.
The company was incorporated in 1997 and operates out of South San Francisco, California. Its shares trade on the NASDAQ under the ticker CYTK.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- cytokinetics.com
Cytokinetics GekkoIndex: the smart money zone
Cytokinetics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.7, in the Buying zone, up 2 points over five sessions.
71.7Buying
Up 2 points over five sessions, from the Accumulation zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 30 | +4.9% | +6.0% | ||
| Accumulation | 271 | +0.8% | −1.2% | ||
| Neutral | 345 | −0.9% | +1.0% | ||
| Distribution | 24 | −0.4% | −0.3% | ||
| Selling | 2 | Too few readings yet | |||
Average CYTK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the CYTK price, zone by zone.Track CYTK in Gekko
Is Cytokinetics stock overvalued? Gekko Fair Value
Cytokinetics trades 25.2% below Gekko Fair Value of $88.50, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cytokinetics shares are worth, recalculated every trading day.
$88.50
Gekko Fair Value, Sep 29, 2026
25.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CYTK in Gekko
Cytokinetics insider and Congress trading
No open-market insider purchases were filed for Cytokinetics, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Ray Cisneros House, CA, purchase | $1,001 - $15,000 | Jul 3 traded Jun 30 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Cytokinetics has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2025
- $21.33M
- As a share of market cap
- 0.26%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds CYTK.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Cytokinetics earnings: next date and track record
Cytokinetics reports on Nov 4, 2026, after the close (36 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 36 days away
- EPS estimate
- −$1.45
- Revenue estimate
- $39.88M
4 of 8reports beat the EPS estimate
±5.7%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Cytokinetics reported strong Q2 2026 commercial momentum for MYQORZO, with launch velocity exceeding expectations just 5 months post-launch. The company launched MYQORZO in Germany and received UK Marketing Authorization with concurrent NICE reimbursement recommendation. ACACIA-HCM Phase III trial for aficamten in nonobstructive HCM met both dual primary endpoints, with an sNDA submission planned for Q4 2026. The company also completed a balance sheet financing during the quarter.
- Guidance
- Cytokinetics plans to submit a supplemental NDA for aficamten in nHCM in Q4 2026. Additional European MYQORZO launches are expected over the next 6-12 months, with UK full launch anticipated later in 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$1.50 est −$1.63 | $28.62M est $17.59M | −2.7% |
| May 5, 2026 | −$1.67 est −$1.65 | $19.36M est $8.52M | +13.3% |
| Feb 24, 2026 | −$1.50 est −$1.56 | $17.76M est $6.93M | −7.9% |
| Nov 5, 2025 | −$1.54 est −$1.59 | $1.94M est $6.05M | +1.1% |
| Aug 7, 2025 | −$1.12 est −$1.34 | $66.77M est $2.07M | −2.9% |
| May 6, 2025 | −$1.36 est −$1.36 | $1.58M est $2.79M | −9.9% |
| Feb 27, 2025 | −$1.26 est −$1.17 | $16.93M est $14.26M | −1.8% |
| Nov 6, 2024 | −$1.36 est −$1.24 | — | +6.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Cytokinetics stock forecast and analyst price targets
Analysts’ average 12-month price target for Cytokinetics is $109.90, +66.1% from the last close, from 15 firms rating the stock in the last 90 days.
$109.90consensus 12-month target, +66.1% from the last close
Now $66.16Avg $109.90
Low $85High $146
Each firm’s latest rating in the last 90 days: 15 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 10 | RBC Capital | $112 | +69.3% |
| Sep 1 | RBC Capital | $112 | +69.3% |
| Sep 1 | Truist Financial | $112 | +69.3% |
| Aug 31 | H.C. Wainwright | $140 | +111.6% |
| Aug 31 | Evercore ISI | $100 | +51.1% |
+6.0%average 20-day move after past Buying readings
+3.9%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Cytokinetics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Cytokinetics averaged +3.9% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.7% | 3 of 5 |
| Next 10 trading days | +8.2% | 4 of 5 |
| Next 15 trading days | +8.3% | 5 of 5 |
| Next 20 trading days | +3.9% | 4 of 5 |
| Next 30 trading days | +7.6% | 4 of 5 |
For scale, CYTK’s typical 20-trading-day move in either direction is about 7.7%.
Cytokinetics market cap and key statistics
Cytokinetics’s market cap is $8.23B and revenue of $67.67M over the last twelve months.
Valuation
- Market cap
- $8.23B
- Forward P/E
- 117.7
- EPS, TTM
- −$7.22
- Gekko Fair Value
- $88.50
Trading
- Volume
- 2.55M
- Avg volume, 20 days
- 1.97M
- 52-week high
- $88.31
- 52-week low
- $47.87
- Shares outstanding
- 139.0M
Financials
- Revenue, TTM
- $67.67M
- Profit margin
- 0%
- Return on equity
- -572%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.36
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±7.7%
Cytokinetics stock news this week
Coverage of Cytokinetics this week reads positive: 5 positive, 2 neutral and 0 negative headlines.
- Cytokinetics stock gains 2.15 percent as analysts target USD 109.90AD HOC NEWS, Sep 28
- Cytokinetics (CYTK) Pullback Puts Its Heart Drug Valuation Story Back In FocusSimply Wall Street, Sep 25
- Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein ConferenceTradingView, Sep 25
- Cytokinetics at bernstein healthcare forum: push beyond first launchInvesting.com, Sep 24
- Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 3,500 Shares of StockDefense World, Sep 23
- Form 4 Cytokinetics Inc For: 22 September By Investing.comInvesting.com Nigeria, Sep 23
Cytokinetics peers
Cytokinetics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Cytokinetics stock FAQ
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $8.23B at the Sep 28, 2026 close of $66.16, with 139.0M shares outstanding.
What is the Cytokinetics stock forecast?
The consensus analyst 12-month price target for Cytokinetics is $109.90, +66.1% from the last close. Of the 15 firms that rated the stock in the last 90 days, 14 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Cytokinetics stock overvalued or undervalued?
On Gekko’s estimate Cytokinetics is undervalued: the Sep 28, 2026 close of $66.16 is 25.2% below Gekko Fair Value of $88.50. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Cytokinetics report earnings next?
Cytokinetics is expected to report on Nov 4, 2026, after the market closes (36 days away). Analysts expect earnings of −$1.45 per share on revenue of $39.88M. Cytokinetics beat the earnings estimate in 4 of its last 8 reports, moving 5.7% on average across the report.
What is Cytokinetics’s 52-week high and low?
Cytokinetics’s 52-week high is $88.31 and its 52-week low is $47.87; it closed at $66.16 on Sep 28, 2026, +38.3% over the past year. Over the last five years the shares peaked at $110.25 on Jan 8, 2024.
Is Cytokinetics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Cytokinetics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.